Cargando…

Integrated single-cell analysis revealed immune dynamics during Ad5-nCoV immunization

Coronavirus disease 2019 (COVID-19), driven by SARS-CoV-2, is a severe infectious disease that has become a global health threat. Vaccines are among the most effective public health tools for combating COVID-19. Immune status is critical for evaluating the safety and response to the vaccine, however...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cao, Qiqi, Wu, Shipo, Xiao, Chuanle, Chen, Shuzhen, Chi, Xiangyang, Cui, Xiuliang, Tang, Hao, Su, Wenru, Zheng, Yingfeng, Zhong, Jiayong, Li, Zhaomin, Li, Fang, Chen, Haijia, Hou, Lihua, Wang, Hongyang, Wen, Wen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Singapore 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8352953/ https://www.ncbi.nlm.nih.gov/pubmed/34373443 http://dx.doi.org/10.1038/s41421-021-00300-2

Ejemplares similares

Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing
por: Wen, Wen, et al.
Publicado: (2020)

Author Correction: Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing
por: Wen, Wen, et al.
Publicado: (2020)

Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients
por: Zhang, Zhe, et al.
Publicado: (2023)

Lung-Targeted Transgene Expression of Nanocomplexed Ad5 Enhances Immune Response in the Presence of Preexisting Immunity
por: Yang, Yilong, et al.
Publicado: (2023)

Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
por: Li, Jingxin, et al.
Publicado: (2022)

A human circulating immune cell landscape in aging and COVID-19
por: Zheng, Yingfeng, et al.
Publicado: (2020)

Innate Immune Responses of Vaccinees Determine Early Neutralizing Antibody Production After ChAdOx1nCoV-19 Vaccination
por: Shen, Ching-Fen, et al.
Publicado: (2022)

Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trial
por: Jin, Lairun, et al.
Publicado: (2022)

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial
por: Wu, Shipo, et al.
Publicado: (2021)

Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia
por: Greinacher, Andreas, et al.
Publicado: (2021)

Unravelling the enhanced vaccine immunity by heterologous KCONVAC/Ad5-nCoV COVID-19 vaccination
por: Zhao, Weijun, et al.
Publicado: (2022)

Multi-dimensional single-cell characterization revealed suppressive immune microenvironment in AFP-positive hepatocellular carcinoma
por: He, Huisi, et al.
Publicado: (2023)

The noncoding and coding transcriptional landscape of the peripheral immune response in patients with COVID‐19
por: Tang, Hao, et al.
Publicado: (2020)

A Case Report of Immune Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
por: Kim, Gyungah, et al.
Publicado: (2021)

Vaccine‐induced immune thrombotic thrombocytopenia with ChAdOx1 nCoV‐19 is rare in Asia
por: Boonyawat, Kochawan, et al.
Publicado: (2022)

Immune thrombocytopenic purpura after vaccination with COVID-19 vaccine (ChAdOx1 nCov-19)
por: Paulsen, Finn-Ole, et al.
Publicado: (2021)

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
por: Sheng, Wang-Huei, et al.
Publicado: (2022)

The Humoral Immune Response of the ChAdOx1 nCoV-19 Vaccine in Maintenance Dialysis Patients without Prior COVID-19 Infection
por: Cheng, Chung-Yi, et al.
Publicado: (2022)

Double high-dose immunoglobulin for ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia()
por: Huang, Ching-Tai, et al.
Publicado: (2021)

Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration
por: Nicolai, Leo, et al.
Publicado: (2022)

Thrombus Distribution in Vaccine-induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
por: Rogers, Priya, et al.
Publicado: (2022)

Neutralizing antibodies levels are increased in individuals with heterologous vaccination and hybrid immunity with Ad5-nCoV in the north of Mexico
por: Cervantes-Luevano, Karla, et al.
Publicado: (2022)

Immunogenicity Differences of the ChAdOx1 nCoV-19 Vaccine According to Pre-Existing Adenovirus Immunity
por: Kim, Jinnam, et al.
Publicado: (2023)

Functional analysis of human circulating immune cells based on high-dimensional mass cytometry
por: Liu, Xiuxing, et al.
Publicado: (2022)

Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea
por: Jeon, Minji, et al.
Publicado: (2021)

ChAdOx1 nCOV-19 vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis (CVST)
por: Suresh, Preethi, et al.
Publicado: (2021)

Vaccination-associated immune thrombocytopenia possibly due to ChAdOx1 nCoV-19 (Covishield) coronavirus vaccine
por: Sivaramakrishnan, Prakash, et al.
Publicado: (2022)

Serological immune response following ChAdOx1 nCoV-19 vaccine (Covishield) in patients with liver cirrhosis
por: Katiyar, Harshita, et al.
Publicado: (2022)

Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield(®)) in Patients with Liver Cirrhosis
por: Goel, Amit, et al.
Publicado: (2022)

Thrombosis with Thrombocytopenia Syndrome (TTS) After ChAdOx1 nCoV-19 Immunization: An Investigative Case Report
por: Jain, Nityanand, et al.
Publicado: (2023)

An Immunobridging Study to Evaluate the Neutralizing Antibody Titer in Adults Immunized with Two Doses of Either ChAdOx1-nCov-19 (AstraZeneca) or MVC-COV1901
por: Estrada, Josue Antonio, et al.
Publicado: (2022)

Comparative immunogenicity analysis of intradermal versus intramuscular immunization with a recombinant human adenovirus type 5 vaccine against Ebola virus
por: Zhang, Zhe, et al.
Publicado: (2022)

Effects of poor sleep on the immune cell landscape as assessed by single-cell analysis
por: Liu, Xiuxing, et al.
Publicado: (2021)

Rapid progressive vaccine-induced immune thrombotic thrombocytopenia with cerebral venous thrombosis after ChAdOx1 nCoV-19 (AZD1222) vaccination: A case report
por: Jiang, Shin-Kuang, et al.
Publicado: (2022)

Treatment of ChAdOx1 nCoV-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia Related Acute Ischemic Stroke
por: Kenda, Jana, et al.
Publicado: (2021)

Breakthrough infections and waning immune responses with ChAdOx1 nCoV‐19 or mRNA vaccine in healthcare workers
por: Lim, So Yun, et al.
Publicado: (2022)

Durability of Immune Response to ChAdOx1-nCoV-19 Vaccine in Solid Cancer Patients Undergoing Anticancer Treatment
por: Wanchaijiraboon, Passakorn, et al.
Publicado: (2022)

Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine
por: Benkeser, David, et al.
Publicado: (2023)

Effects of sex and aging on the immune cell landscape as assessed by single-cell transcriptomic analysis
por: Huang, Zhaohao, et al.
Publicado: (2021)

Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial
por: Tang, Rong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n18ihd6l0u8utt01o7i8srut2t